---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-275902"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:26:02.209593+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Artiva reports AlloNK shows deep B-cell depletion in 32 autoimmune patients; FDA interaction planned 1H 2026

## Summary
- 32 patients dosed with AlloNK + anti-CD20 mAb as outpatients at community rheumatology sites; no CRS, ICANS or GvHD.
- No Grade 3+ AlloNK-related TEAEs, no discontinuations; only one hospitalization (unrelated skin infection).
- All 23 analyzed patients had undetectable peripheral CD19+ B-cells by Day 13; high-sensitivity assay confirms depletion.
- B-cell depletion depth comparable to CD19-auto-CAR-T, greater than rituximab alone per published studies.
- Plans to share initial RA response data from >15 patients and align with FDA on pivotal trial design in 1H 2026.

## SEC filing metadata
- accession: 0001193125-25-275902
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000119312525275902/0001193125-25-275902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000119312525275902/artv-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-275902
- JSON: https://secwatch.observer/filing/0001193125-25-275902.json
- Plain text: https://secwatch.observer/filing/0001193125-25-275902.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.